These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 36965205)

  • 1. Independent role of Alzheimer's disease genetics and C-reactive protein on cognitive ability in aging.
    Supiyev A; Karlsson R; Wang Y; Koch E; Hägg S; Kauppi K
    Neurobiol Aging; 2023 Jun; 126():103-112. PubMed ID: 36965205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E moderates the association between non-APOE polygenic risk score for Alzheimer's disease and aging on preclinical cognitive function.
    Xu Y; Sun Z; Jonaitis E; Deming Y; Lu Q; Johnson SC; Engelman CD
    Alzheimers Dement; 2024 Feb; 20(2):1063-1075. PubMed ID: 37858606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polygenic risk scores for Alzheimer's disease in relation to cognitive change: A representative sample from the general population followed over 16 years.
    Najar J; Thorvaldsson V; Kern S; Skoog J; Waern M; Zetterberg H; Blennow K; Skoog I; Zettergren A
    Neurobiol Dis; 2023 Dec; 189():106357. PubMed ID: 37977433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid-β and APOE genotype predict memory decline in cognitively unimpaired older individuals independently of Alzheimer's disease polygenic risk score.
    Tomassen J; den Braber A; van der Lee SJ; Reus LM; Konijnenberg E; Carter SF; Yaqub M; van Berckel BNM; Collij LE; Boomsma DI; de Geus EJC; Scheltens P; Herholz K; Tijms BM; Visser PJ
    BMC Neurol; 2022 Dec; 22(1):484. PubMed ID: 36522743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive trajectories diverge by genetic risk in a preclinical longitudinal cohort.
    Vasiljevic E; Koscik RL; Jonaitis E; Betthauser T; Johnson SC; Engelman CD
    Alzheimers Dement; 2023 Jul; 19(7):3108-3118. PubMed ID: 36723444
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Pathway-Specific Polygenic Risk Scores for Alzheimer's Disease (AD) on Rate of Change in Cognitive Function and AD-Related Biomarkers Among Asymptomatic Individuals.
    Xu Y; Vasiljevic E; Deming YK; Jonaitis EM; Koscik RL; Van Hulle CA; Lu Q; Carboni M; Kollmorgen G; Wild N; Carlsson CM; Johnson SC; Zetterberg H; Blennow K; Engelman CD
    J Alzheimers Dis; 2023; 94(4):1587-1605. PubMed ID: 37482996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations of circulating C-reactive proteins, APOE ε4, and brain markers for Alzheimer's disease in healthy samples across the lifespan.
    Wang Y; Grydeland H; Roe JM; Pan M; Magnussen F; Amlien IK; Watne LO; Idland AV; Bertram L; Gundersen TE; Pascual-Leone A; Cabello-Toscano M; Tormos JM; Bartres-Faz D; Drevon CA; Fjell AM; Walhovd KW
    Brain Behav Immun; 2022 Feb; 100():243-253. PubMed ID: 34920091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alzheimer's polygenic risk scores are associated with cognitive phenotypes in Down syndrome.
    Gorijala P; Aslam MM; Dang LT; Xicota L; Fernandez MV; Sung YJ; Fan KH; Feingold E; Surace EI; Chhatwal JP; Hom CL; ; ; Hartley SL; Hassenstab J; Perrin RJ; Mapstone M; Zaman SH; Ances BM; Kamboh MI; Lee JH; Cruchaga C
    Alzheimers Dement; 2024 Feb; 20(2):1038-1049. PubMed ID: 37855447
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of increasing levels of blood C-reactive protein on the inflammatory loci SPI1 and CD33 in Alzheimer's disease.
    Huang J; Tao Q; Ang TFA; Farrell J; Zhu C; Wang Y; Stein TD; Lunetta KL; Massaro J; Mez J; Au R; Farrer LA; Qiu WQ; Zhang X;
    Transl Psychiatry; 2022 Dec; 12(1):523. PubMed ID: 36550123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utility of an Alzheimer's Disease Risk-Weighted Polygenic Risk Score for Predicting Rates of Cognitive Decline in Preclinical Alzheimer's Disease: A Prospective Longitudinal Study.
    Porter T; Burnham SC; Milicic L; Savage G; Maruff P; Lim YY; Li QX; Ames D; Masters CL; Rainey-Smith S; Rowe CC; Salvado O; Groth D; Verdile G; Villemagne VL; Laws SM;
    J Alzheimers Dis; 2018; 66(3):1193-1211. PubMed ID: 30412495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Digital Clock Drawing as an Alzheimer's Disease Susceptibility Biomarker: Associations with Genetic Risk Score and APOE in Older Adults.
    Thompson LI; Cummings M; Emrani S; Libon DJ; Ang A; Karjadi C; Au R; Liu C
    J Prev Alzheimers Dis; 2024; 11(1):79-87. PubMed ID: 38230720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The association of APOE ε4 with cognitive function over the adult life course and incidence of dementia: 20 years follow-up of the Whitehall II study.
    Gharbi-Meliani A; Dugravot A; Sabia S; Regy M; Fayosse A; Schnitzler A; Kivimäki M; Singh-Manoux A; Dumurgier J
    Alzheimers Res Ther; 2021 Jan; 13(1):5. PubMed ID: 33397450
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk.
    Corlier F; Hafzalla G; Faskowitz J; Kuller LH; Becker JT; Lopez OL; Thompson PM; Braskie MN
    Neuroimage; 2018 May; 172():118-129. PubMed ID: 29357308
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effect of the APOE Genotype on Individual BrainAGE in Normal Aging, Mild Cognitive Impairment, and Alzheimer's Disease.
    Löwe LC; Gaser C; Franke K;
    PLoS One; 2016; 11(7):e0157514. PubMed ID: 27410431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of CD33 rs3865444:C˃A polymorphism with a reduced risk of late-onset Alzheimer's disease in Slovaks is limited to subjects carrying the APOE ε4 allele.
    Javor J; Ďurmanová V; Párnická Z; Minárik G; Králová M; Pečeňák J; Vašečková B; Režnáková V; Šutovský S; Gmitterová K; Hromádka T; Peterajová Ľ; Shawkatová I
    Int J Immunogenet; 2020 Oct; 47(5):397-405. PubMed ID: 32333488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid and APOE ε4 interact to influence short-term decline in preclinical Alzheimer disease.
    Mormino EC; Betensky RA; Hedden T; Schultz AP; Ward A; Huijbers W; Rentz DM; Johnson KA; Sperling RA; ; ;
    Neurology; 2014 May; 82(20):1760-7. PubMed ID: 24748674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of polygenic risk for Alzheimer's disease on rate of cognitive decline in normal aging.
    Kauppi K; Rönnlund M; Nordin Adolfsson A; Pudas S; Adolfsson R
    Transl Psychiatry; 2020 Jul; 10(1):250. PubMed ID: 32709845
    [TBL] [Abstract][Full Text] [Related]  

  • 18. APOE ε4, Alzheimer's disease neuropathology and sleep disturbance, in individuals with and without dementia.
    Blackman J; Love S; Sinclair L; Cain R; Coulthard E
    Alzheimers Res Ther; 2022 Mar; 14(1):47. PubMed ID: 35354468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein E epsilon4 genotype as a risk factor for cognitive decline and dementia: data from the Canadian Study of Health and Aging.
    Hsiung GY; Sadovnick AD; Feldman H
    CMAJ; 2004 Oct; 171(8):863-7. PubMed ID: 15477624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Memory performance in healthy elderly without Alzheimer's disease: effects of time and apolipoprotein-E.
    Mayeux R; Small SA; Tang M; Tycko B; Stern Y
    Neurobiol Aging; 2001; 22(4):683-9. PubMed ID: 11445269
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.